ABBV · 10-Q · 2026Q3 · Full report

Immunology Product Demand and Expansion

AbbVie Inc. · 2026-11-03 · Importance 59 · Surprise 48 · In source text

Skyrizi net revenues increased 23% in the third quarter and 25% in the first nine months of 2026, driven by continued strong market share uptake and market growth across indications. Rinvoq net revenues increased 24% and 23% in those periods, respectively, also driven by market share uptake and market growth. By contrast, Humira net revenues declined 31% and 36%, primarily because of direct biosimilar competition following loss of exclusivity.

Key facts

• Humira net revenues decreased 31% in the three months and 36% in the nine months ended September 30, 2026, primarily due to direct biosimilar competition following loss of exclusivity. source
• In February 2026, AbbVie announced positive topline Phase 3 AFFIRM results for Skyrizi subcutaneous induction in adults with moderately to severely active Crohn’s disease. source
• In June 2026, the European Commission approved Skyrizi for children aged six and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. source
• In June 2026, the FDA approved Skyrizi for children aged six and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, or who have active psoriatic arthritis. source
• In August 2026, AbbVie submitted an application to the European Medicines Agency for Skyrizi subcutaneous induction to treat adults with moderately to severely active Crohn’s disease. source
• In October 2026, the FDA approved Skyrizi subcutaneous induction for adults with moderately to severely active Crohn’s disease. source
• In February 2026, AbbVie submitted a U.S. FDA application for Rinvoq to treat adult and adolescent patients with non-segmental vitiligo. source
• In April 2026, AbbVie submitted a U.S. FDA application for Rinvoq to treat adults and adolescents with severe alopecia areata. source

Impact estimates